Successful Entry into the U.S. Generic Diabetes Market

Zhejiang Huahai Pharmaceutical (600521.SH)'s U.S. subsidiary, Prinston Pharmaceutical, has received FDA approval for its generic version of Metformin Hydrochloride Extended-Release tablets, a treatment for Type 2 Diabetes Mellitus (ANDA 208880). The approved formulation is available in 500mg and 750mg strengths and offers the same efficacy as the original drug, such as Glucophage XR. This approval is expected to be a significant milestone for Huahai Pharmaceutical, enabling it to significantly expand its affordable generic portfolio in the U.S., the world's largest diabetes market.

Key Mechanism in Metabolic Disease Treatment and Improved Patient Convenience

Metformin works by activating AMP-activated protein kinase (AMPK), which inhibits glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the drug slowly in the body, reducing gastrointestinal side effects compared to immediate-release formulations and improving patient adherence with once-daily dosing. This allows diabetes patients to manage their blood sugar levels more effectively and sustainably with fewer side effects.

Competitive Landscape in the U.S. Diabetes Market and Pricing Strategy

Currently, the U.S. market for Type 2 diabetes treatments is dominated by newer drugs such as Jardiance (an SGLT2 inhibitor) and Ozempic (a GLP-1 receptor agonist). However, metformin remains firmly established as a first-line therapy and continues to have strong demand in the global metformin market, valued at approximately $3.62 billion. Prinston plans to aggressively expand its market share in the U.S. by leveraging its cost-competitive manufacturing compared to existing generic products such as Fortamet and Glumetza.

Recovery of Huahai Pharmaceutical's Global Supply Chain and Enhanced Regulatory Reliability

Huahai Pharmaceutical previously faced a significant crisis in the U.S. market due to the detection of impurities in Valsartan, leading to regulatory risks and a decline in brand reputation. The FDA approval of the metformin extended-release tablets demonstrates that Huahai Pharmaceutical has regained trust in its production facilities and cGMP compliance, and has restored its relationship with regulatory authorities. In the future, the company plans to continue expanding its portfolio of chronic disease treatments based on its secured and stable production capacity, and will pursue global revenue diversification.